Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 04, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 300,000 ordinary shares of 25 pence each.
- Purchase Price: 1,491.66 pence per share.
- Treasury Shares Held: 123,458,000 shares following the transaction.
- Shares in Issue: 5,825,106,461 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed the purchase of 300,000 shares on November 04, 2005, increasing its Treasury share holdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (300,000 shares at 1,491.66 pence) against the company's cash position in broader financial reports.
- Confirm the total number of shares in issue (5,825,106,461) and Treasury shares (123,458,000) against the latest capitalization table.
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual performance data.